Oncology Drugs In The Pipeline
60HemOnc today MAY 25, 2013 Healio.com/HemOncOncology Drugs in the PipelineHemOnc Today presents the most recent information about oncology drugs in the pipeline. Drugs listed here are in phase 2 or phase 3 development for a variety ofindications. Clinicians can use this chart as a quick reference to learn about the status of those drugs that may be clinically significant to their practice.Generic name (Brand name, Manufacturer) Indication(s)Development status131I-chTNT-1/B mAb (Cotara, Peregrine Pharmaceuticals)glioblastomaphase 218F-fluorothymidine (Merck)breast cancer diagnosisphase 2A6 (Angstrom Pharmaceuticals)ovarian cancerphase 2abagovomab (Menarini)ovarian cancerphase 3abexinostat (Pharmacyclics)follicular lymphoma, mantle cell lymphomaphase 2ABI-008 (Celgene)prostate cancerphase 2ABIO-0501 (Abiogen Pharma)chronic myeloid leukemiaphase 2abiraterone (Zytiga, Janssen Biotech)breast cancer/prostate cancerphase 2/phase 3ABT-888 (Abbott Laboratories)breast cancer, colorectal cancer, fallopian tube cancer, lymphoma, melanoma, non–small cell lung cancer, ovarian cancerphase 2ACE-041 (Acceleron Pharma)head and neck cancersphase 2acolbifene (EndoCeutics)breast cancerphase 2ACY-1215 (Acetylon Pharmaceuticals)myelomaphase 2ado-trastuzumab emtansine (Kadcyla, Genentech)first-line and third-line HER-2–positive breast cancerphase 3ADXS-HPV(Advaxis)cervical cancerphase 2AE37 peptide vaccine (Antigen Express)breast cancerphase 2AEE788 (Novartis Pharmaceuticals)glioblastomaphase 2AEG35156 (Aegera Therapeutics)acute myelogenous leukemia, chronic lymphocytic leukemia, B-celllymphomaphase 2AEZS-108 (Aeterna Zentaris)bladder cancer, endometrial cancer, ovarian cancer, prostate cancerphase 2afatinib (Boehringer Ingelheim)glioblastoma/breast cancer, non–small cell lung cancer, head and neckcancersphase 2/phase 3afimoxifene (Ascend Therapeutics)breast cancer preventionphase 2aflibercept (Zaltrap; Regeneron Pharmaceuticals, Sanofi)prostate cancerphase 3AFP464 (Kirax)breast cancerphase 2AGS-003 (Argos Therapeutics)renal cancerphase 2AGS-005 (Argos Therapeutics)chronic lymphocytic leukemiaphase 2albumin-bound paclitaxel (Abraxane, Celgene)bladder cancer, breast cancer, ovarian cancer/pancreatic cancer, skincancer, non–small cell lung cancerphase 2/phase 3algenpantucel-L (HyperAcute Pancreas, NewLink Genetics)pancreatic cancerphase 3AlloStim (Immunovative Therapies)hematologic malignanciesphase 2ALT-801 (Altor BioScience)melanoma, myeloma, urogenital cancerphase 2AME-133v (Mentrik Biotech)non-Hodgkin’s lymphomaphase 2AMG888/U3-1287 (Amgen/Daiichi Sankyo)non–small cell lung cancerphase 2aminopterin (Syntrix Biosystems)acute lymphoblastic leukemiaphase 2amonafide (Quinamed, Cephalon)breast cancer, ovarian cancer, prostate cancerphase 2amrubicin (Celgene)breast cancer/small cell lung cancerphase 2/phase 3amuvatinib (Astex Pharmaceuticals)small cell lung cancerphase 2READ PERSPECTIVEon this drug from TobennaNwizu, MD, on page 76.
61HemOnc today MAY 25, 2013 Healio.com/HemOncOncology Drugs in the PipelineGeneric name (Brand name, Manufacturer) Indication(s)Development statusanti-CD22 antibody-drug conjugate (Genentech)diffuse large B-cell lymphoma, non-Hodgkin’s lymphomaphase 2anti-CD79b antibody-drug conjugate (Genentech)diffuse large B-cell lymphoma, non-Hodgkin’s lymphomaphase 2anti-EGFL7 MAb (Genentech)colorectal cancer, non–small cell lung cancerphase 2anti-Her3/EGFR DAF MAb (Genentech)colorectal cancer, head and neck cancersphase 2anti-MUC1 mAb (Quest PharmaTech)pancreatic cancerphase 2anti-PSCA mAb (Agensys/Astellas)pancreatic cancerphase 2AP1903 (Bellicum Pharmaceuticals)prostate cancerphase 2AP5346 (Access Pharmaceuticals)head and neck cancersphase 2apaziquone (Eoquin, Allergan)bladder cancerphase 3APC-100 (Adamis Pharmaceuticals)prostate cancerphase 2APN301 (Apeiron Biologics)melanoma, pediatric neuroblastomaphase 2apricoxib (Tragara Pharmaceuticals)non–small cell lung cancer, pancreatic cancerphase 2AR-42 (Arno Therapeutics)chronic lymphocytic leukemia, lymphoma, multiple myelomaphase 2AR-67 (Arno Therapeutics)glioblastoma, myelodysplastic syndromesphase 2ARC-100 (Archer Biosciences)breast cancer, glioblastoma, melanoma, neuroblastoma, prostatecancerphase 2ARN-509 (Aragon Pharmaceuticals)prostate cancerphase 2ARRY-162 (Array BioPharma)melanomaphase 2ARRY-520 (Array BioPharma)acute myelogenous leukemia, myelomaphase 2ascorbic acid/menadione (Apatone, IC-MedTech)prostate cancerphase 2astuprotimut-R (GlaxoSmithKline)non–small cell lung cancer, melanomaphase 3AT-101 (Ascenta Therapeutics)chronic lymphocytic leukemia, esophageal cancer, glioblastoma, nonHodgkin’s lymphoma, non–small cell lung cancer, prostate cancerphase 2AT13387 (Astex Pharmaceuticals)gastrointestinal stromal tumorsphase 2AT7519 (Astex Pharmaceuticals)chronic lymphocytic leukemia, mantle cell lymphoma, myelomaphase 2AT9283 (Astex Pharmaceuticals)acute myelogenous leukemia, myelomaphase 2autologous stem cell therapy (California Stem Cells)melanomaphase 2AUY922 (Novartis)breast cancer, gastrointestinal stromal tumors, myeloma, non–small celllung cancerphase 2AVX701 (AlphaVax)colorectal cancer preventionphase 2axitinib (Inlyta, Pfizer)liver cancer, thyroid cancer/renal cell carcinomaphase 2/phase 3azacitidine (Vidaza, Celgene)solid tumors/acute myelogenous leukemia, lymphomaphase 2/phase 3AZD8931 (AstraZeneca)breast cancerphase 2bafetinib (CytRx)chronic lymphocytic leukemia, prostate cancerphase 2bavituximab (Peregrine Pharmaceuticals)liver cancer, non–small cell lung cancer, pancreatic cancerphase 2BAY 80-6946 (Bayer Healthcare)non-Hodgkin’s lymphomaphase 2BAY 86-5044 (Bayer HealthCare)breast cancerphase 2BAY 86-9766 (Ardea Biosciences)liver cancer, pancreatic cancerphase 2BC-819 (BioCancell Therapeutics)bladder cancer, ovarian cancer, pancreatic cancerphase 2
62HemOnc today MAY 25, 2013 Healio.com/HemOncOncology Drugs in the PipelineGeneric name (Brand name, Manufacturer) Indication(s)Development statusbelagenpumatucel-L (Lucanix, NovaRx)non–small cell lung cancerphase 3belinostat (Spectrum Pharmaceuticals)acute myelogenous leukemia, colorectal cancer, liver cancer, mesothelioma, non–small cell lung cancer, ovarian cancer, peripheral B-celllymphoma, peripheral T-cell lymphoma, peritoneal cancer, thymomaphase 2bendamustine (Treanda, Cephalon)acute lymphoblastic leukemia, acute myelogenous leukemia, mantlecell lymphoma, multiple myeloma/non-Hodgkin’s lymphomaphase 2/phase 3bevacizumab (Avastin, Genentech)breast cancer, colorectal cancer, glioblastoma, high-risk carcinoidtumor, non–small cell lung cancer, ovarian cancerphase 3BHQ880 (Novartis)myelomaphase 2BI-695500 (Boehringer Ingelheim)non-Hodgkin’s lymphomaphase 3BI-811283 (Boehringer Ingelheim)acute myelogenous leukemiaphase 2BIIB 2024 (Biogen Idec)breast cancer, gastrointestinal stromal tumorsphase 2BiovaxID (BioVest International)mantle cell lymphoma/follicular lymphomaphase 2/phase 3birinapant (TetraLogic)acute myelogenous leukemiaphase 2BIW-8962 (Kyowa Hakko Kirin Pharma)multiple myelomaphase 2BKM120 (Novartis)breast cancer, endometrial cancer, glioblastoma, non–small cell lungcancer, non-Hodgkin’s lymphoma, urogenital cancerphase 2blinatumomab (Amgen)acute myelogenous leukemia, non-Hodgkin’s lymphomaphase 2BNC105 (Bionomics)kidney cancerphase 2BNP1350 (Karenitecin, BioNumerik Pharmaceuticals)non–small cell lung cancer/ovarian cancerphase 2/phase 3bortezomib (Velcade, Millennium)adenocarcinoma, diffuse large B-cell lymphoma, T-cell prolymphocyticleukemia/mantle cell lymphoma, non-Hodgkin’s B-cell lymphomaphase 2/phase 3bosutinib (Pfizer)chronic myeloid leukemiaphase 3BPX-101 (Bellicum Pharmaceuticals)prostate cancerphase 2breast cancer vaccine (Quantum Immunologics)breast cancerphase 2brentuximab vedotin (Adcetris; Millennium Pharmaceuticals,Seattle Genetics)CD30-positive hematologic malignancies, non-Hodgkin’s lymphoma/Hodgkin’s lymphoma, T-cell lymphomaphase 2/phase 3brivanib (Bristol-Myers Squibb)colorectal cancer, sarcoma / liver cancerphase 2/phase 3c31510 (Cytotech)basal cell carcinoma, squamous cell carcinomaphase 2cabozantinib (Exelixis)breast cancer, non–small cell lung cancer, ovarian cancer/castrationresistant prostate cancer, thyroid cancerphase 2/phase 3calaspargase pegol (Sigma-Tau Pharmaceuticals)acute lymphoblastic leukemiaphase 3cancer vaccine (MabVax Therapeutics)prostate cancerphase 2cancer vaccine E75 (NeuVax, Galena Biopharma)prostate cancer/breast cancerphase 2/phase 3canfosfamide (Telcyta, Telik)diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin’slymphoma/non–small cell lung cancer, ovarian cancerphase 2/phase 3capecitabine (Xeloda, Genentech)biliary cancer, esophageal cancerphase 2carfilzomib (Kyprolis, Onyx Pharmaceuticals)myelomaphase 3carlecortemcel-L (Gamida Cell)hematologic malignanciesphase 3catumaxomab (Fresenius Biotech)malignant ascites, ovarian cancerphase 2CB-10-01 cancer vaccine (Cosmo Pharmaceuticals)melanomaphase 2CB3304 (Cougar Biotechnology)multiple myelomaphase 2CBLC102 (Cleveland BioLabs/Incuron)prostate cancerphase 2READ PERSPECTIVEon this drug from MaurieMarkman, MD, on page 75.
63HemOnc today MAY 25, 2013 Healio.com/HemOncOncology Drugs in the PipelineGeneric name (Brand name, Manufacturer) Indication(s)Development statusCBP-501 (CanBas)mesothelioma, non–small cell lung cancerphase 2CC-223 (Celgene)solid tumorsphase 2CC-486 (Celgene)acute myelogenous lymphoma, myelodysplastic syndromesphase 2cenersen (Eleos)acute myelogenous leukemiaphase 2CEP-9722 (Cephalon)non–small cell lung cancerphase 2cetuximab (Erbitux; Bristol-Myers Squibb, Eli Lilly)colorectal cancer, gastric cancerphase 3ch.14.18 mAb (United Therapeutics)pediatric neuroblastomaphase 3chk1 inhibitor (Eli Lilly)non–small cell lung cancer, pancreatic cancerphase 2cilengitide (EMD Serono)glioblastoma, prostate cancerphase 3cixutumumab (Eli Lilly)liver cancer, non–small cell lung cancerphase 2CLL immunotherapeutic vaccine (MaxCyte)chronic lymphocytic leukemiaphase 2clodronic acid (Bayer HealthCare)bone metastasesphase 3clofarabine injection (Clolar, Genzyme)acute myelogenous leukemiaphase 3CLR1404-I-124 (Novelos Therapeutics)non–small cell lung cancerphase 2CLR1404-I-131 (Novelos Therapeutics)non–small cell lung cancerphase 2CNDO-109 (Coronado Biosciences)acute myelogenous leukemiaphase 2CO-101 (Clovis Oncology)pancreatic cancerphase 2CO-1686 (Clovis Oncology)non–small cell lung cancerphase 2coxsackievirus A21 (Cavatak, Viralytics)melanomaphase 2CP-18770 (Cephalon)multiple myelomaphase 2CPI-613 (Cornerstone Pharmaceuticals)pancreatic cancerphase 2CPX-1 (Celator Pharmaceuticals)colorectal cancerphase 2CPX-351 (Celator)acute myelogenous leukemiaphase 3crenolanib (AROG Pharmaceuticals)gastrointestinal stromal tumors, glioma, acute myelogenous leukemiaphase 2crizotinib (Xalkori, Pfizer)non–small cell lung cancerphase 3CRS-207 (Aduro BioTech)pancreatic cancerphase 2CT-011 (CureTech)acute myelogenous leukemia, colorectal cancer, diffuse large B-celllymphoma, follicular lymphomaphase 2CTL019 (Novartis/University of Pennsylvania)chronic lymphocytic leukemiaphase 2custirsen (OncoGenex/Teva)non–small cell lung cancer/prostate cancerphase 2/phase 3CV-301 (BN ImmunoTherapeutics)breast cancerphase 2Cvac (Prima BioMed)ovarian cancerphase 3CVX 060 (Pfizer)renal cell carcinomaphase 2cytarabine/daunorubicin (CPX-351, Celator Pharmaceuticals)acute myelogenous leukemiaphase 2D-1MT (NewLink Genetics)breast cancerphase 2dabrafenib (GSK2118436, GlaxoSmithKline)BRAF mutation-positive disease, brain metastases from melanoma,non–small cell lung cancer/melanomaphase 2/phase 3dacomitinib (Pfizer)non–small cell lung cancerphase 3
64HemOnc today MAY 25, 2013 Healio.com/HemOncOncology Drugs in the PipelineGeneric name (Brand name, Manufacturer) Indication(s)Development statusdalotuzumab (Merck)breast cancer, lung cancer, neuroendocrine tumors, pancreatic cancerphase 2danusertib (Nerviano Medical Sciences)chronic myeloid leukemiaphase 2daratumumab (Genmab)multiple myelomaphase 2darbepoetin alfa (Amgen)myelodysplastic syndromesphase 3darinaparsin (ZIO-101, Ziopharm Oncology)liver cancer, T-cell lymphoma, multiple myelomaphase 2dasatinib (Sprycel, Bristol-Myers Squibb)breast cancer, glioblastoma, leukemia, pancreatic cancer/prostatecancerphase 2/phase 3DCC-2036 (Deciphera Pharmaceuticals)acute lymphoblastic leukemia, chronic myeloid leukemiaphase 2DCVax-Brain (Northwest Biotherapeutics)glioblastomaphase 2decitabine (Dacogen, Eisai)acute myelogenous leukemiaphase 3degarelix (Firmagon, Ferring)prostate cancerphase 3delanzomib (Cephalon)myelomaphase 2denileukin diftitox (Ontak, Eisai)melanomaphase 2denosumab (Xgeva, Amgen)giant cell tumor of bone/prevention of bone metastases, bone damagein patients with multiple myelomaphase 2/phase 3dimesna (Tavocept, BioNumerik Pharmaceuticals)lung cancerphase 3dinaciclib (Merck)chronic lymphocytic leukemiaphase 3DN24-02 dendritic cell vaccine (Dendreon)urogenital cancerphase 2dovitinib (TKI258, Novartis)breast cancer, endometrial cancer, glioblastoma, melanoma, multiplemyeloma, prostate cancer, urothelial cancer/kidney cancerphase 2/phase 3doxorubicin-eluting beads (DC Bead; Bayer HealthCare, Biocompatibles)liver cancerphase 2doxorubicin liposomal (Myocet, Sopherion Therapeutics)breast cancerphase 3doxorubicin liposomal (ThermoDox)breast cancer, colorectal cancer / liver cancerphase 2/phase 3E7050 (Eisai)gastric cancer, glioblastoma, head and neck cancers, liver cancer,melanomaphase 2E7080 (Eisai)glioma, melanoma / thyroid cancerphase 2/phase 3E7820 (Eisai)colorectal cancerphase 2E7850 (Eisai)ovarian cancer, prostate cancer, thyroid cancerphase 2EC20 (Endocyte)non–small cell lung cancer/ovarian cancerphase 2/phase 3EC145 (Endocyte/Merck)non–small cell lung cancer/ovarian cancerphase 2/phase 3ecromeximab (Life Science Pharmaceuticals)melanomaphase 2efatutazone (Daiichi Sankyo)colorectal cancer, non–small cell lung cancer, thyroid cancerphase 2EGEN-001 (Egen)colorectal cancer, fallopian tube cancer, ovarian cancer, peritonealcancerphase 2elacytarabine (Elacyt, Clavis Pharma)acute myelogenous leukemiaphase 3elagolix (Abbott Laboratories)uterine leiomyomaphase 2elesclomol (Synta)non–small cell lung cancer, ovarian cancerphase 2elotuzumab (Bristol-Myers Squibb)multiple myelomaphase 3eltrombopag (Promacta, GlaxoSmithKline)acute myelogenous leukemia, myelodysplastic syndromesphase 2READ PERSPECTIVEon this drug from ManmeetAhluwalia, MD, FACP, on page 76.
65HemOnc today MAY 25, 2013 Healio.com/HemOncOncology Drugs in the PipelineGeneric name (Brand name, Manufacturer) Indication(s)Development statusEMD-525797 (EMD Serono)prostate cancerphase 3emepepimut-S (EMD Serono/Oncothyreon)prostate cancer / non–small cell lung cancerphase 2/phase 3EN3488 (Endo Pharmaceuticals)bladder cancerphase 3encapsulated cell therapy (Rogosin Institute)colorectal cancer, pancreatic cancer, prostate cancerphase 2eniluracil (Adherex Technologies)breast cancerphase 2ENMD-2076 (EntreMed)ovarian cancerphase 2entinostat (Syndax Pharmaceuticals)breast cancer, colorectal cancer, Hodgkin’s lymphoma, kidney cancer,leukemia, non–small cell lung cancerphase 2enzastaurin (Eli Lilly)diffuse large B-cell lymphomaphase 3EPO-806 (Novartis)brain metastases from lung cancer, prostate cancerphase 2epratuzumab (Immunomedics)acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicularlymphomaphase 2epratuzumab Y-90 (Immunomedics)diffuse large B-cell lymphoma, non-Hodgkin’s lymphomaphase 2eribulin (Halaven, Eisai)prostate cancer/non–small cell lung cancer, sarcomaphase 2/phase 3erlotinib (Tarceva, Genentech)brain metastases, breast cancer, ependymoma (children), glioblastoma,gynecologic cancers, head and neck cancers, myelodysplastic syndrome/liver cancer, non–small cell lung cancerphase 2/phase 3etirinotecan pegol (Nektar Therapeutics)platinum-resistant ovarian cancer/breast cancer, colorectal cancerphase 2/phase 3everolimus (Afinitor, Novartis)kidney cancer, diffuse large B-cell lymphoma, mantle cell lymphoma/HER-2–positive breast cancerphase 2/phase 3ezatiostat (Telintra)myelodysplastic syndromesphase 3EZN-2208 (Enzon Pharmaceuticals)breast cancer, colorectal cancerphase 2Fang Vaccine (Gradalis)colorectal cancer, melanoma, ovarian cancerphase 2FG-3019 (FibroGen)pancreatic cancerphase 2ficlatuzumab (AVEO)non–small cell lung cancerphase 2folate binding protein (E39) vaccine (Galena Biopharma)endometrial cancer, ovarian cancerphase 2foretinib (GlaxoSmithKline)head and neck cancers, kidney cancer, non–small cell lung cancerphase 2forodesine (BioCryst Pharmaceuticals)chronic lymphocytic leukemia, cutaneous T-cell lymphomaphase 2fosbretabulin (Zybrestat, OXiGENE)non–small cell lung cancer, ovarian cancerphase 2fostamatinib (AstraZeneca/Rigel Pharmaceuticals)hematologic malignanciesphase 2fulvestrant (Faslodex, AstraZeneca)breast cancerphase 3G-100 prophage cancer vaccine (Agenus)gliomaphase 2G-200 prophage cancer vaccine (Agenus)gliomaphase 2galiximab (Biogen Idec)non-Hodgkin’s lymphomaphase 2ganetespib (Synta Pharmaceuticals)acute lymphoblastic leukemia, acute myelogenous leukemia, breastcancer, chronic myeloid leukemia, colorectal cancer, esophageal cancer,gastric cancer, gastrointestinal stromal tumors, liver cancer, melanoma,pancreatic cancer, prostate cancer/non–small cell lung cancerphase 2/phase 3ganitumab (Amgen)breast cancer, colorectal cancer, sarcoma, small cell lung cancer/pancreatic cancerphase 2/phase 3GDC-0941 (Genentech)breast cancer, non–small cell lung cancerphase 2GDC-0973 (Genentech)melanomaphase 3
66HemOnc today MAY 25, 2013 Healio.com/HemOncOncology Drugs in the PipelineGeneric name (Brand name, Manufacturer) Indication(s)GDC-0980 (Genentech)Development statusbreast cancer, non-Hodgkin’s lymphoma, endometrial cancer, renal cellcarcinomaphase 2gefitinib (Iressa, AstraZeneca)non–small cell lung cancerphase 3GI-4000 (GlobeImmune)colorectal cancer, pancreatic cancerphase 2girentuximab (Rencarex, Wilex)clear cell renal cell carcinomaphase 3girentuximab I-124 (Redectane, Wilex)renal cancerphase 3GL-0817 (Gliknik)multiple myelomaphase 2glembatumumab vedotin (CDX-011, Celldex Therapeutics)breast cancer, melanomaphase 2GliAtak (Advantagene)gliomaphase 2glufosfamide (Eleison Pharmaceuticals)pancreatic cancerphase 3GMB-Vax (Activartis Biotech)glioblastomaphase 2GM-CT-01 (Galectin Therapeutics)colorectal cancerphase 2golnerminogene pradenovec (TNFerade, GenVec)esophageal cancer, head and neck cancers, melanomaphase 2GRN1005 (GlaxoSmithKline)brain metastasesphase 2GRNVAC1 (Argos Therapeutics)acute myelogenous leukemia, prostate cancerphase 2GSK2110183 (GlaxoSmithKline)leukemia, multiple myeloma, ovarian cancerphase 2GSK2130579A (GlaxoSmithKline)acute myelogenous leukemiaphase 2GSK2302024A (GlaxoSmithKline)breast cancerphase 2GS-6624 (Gilead Sciences)colorectal cancer, pancreatic cancerphase 2GTx-758 (GTx)prostate cancerphase 2GVAX Leukemia (BioSante Pharmaceuticals)acute myelogenous leukemia, chronic myeloid leukemiaphase 2GVAX Myeloma (BioSante Pharmaceuticals)multiple myelomaphase 2GVAX Pancreatic (BioSante Pharmaceuticals/Aduro BioTech)pancreatic cancerphase 2GVAX Prostate (BioSante Pharmaceuticals/Aduro BioTech)prostate cancerphase 3HE3235 (Harbor Therapeutics)prostate cancerphase 2HER-2 antigen-specific cancer immunotherapeutic(GlaxoSmithKline)breast cancerphase 2histamine dihydrochloride injection (Ceplene, EpiCept)acute myelogenous leukemiaphase 3HuM195-Bi-213 (Actinium Pharmaceuticals)acute myelogenous leukemiaphase 2I-131 metaiodobenzylguanidine (Azedra, Molecular InsightsPharmaceuticals)paraganglioma, pediatric neuroblastoma, pheochromocytomaphase 2ibritumomab tiuxetan (Zevalin, Spectrum Pharmaceuticals)mantle cell lymphoma/diffuse large B-cell lymphomaphase 2/phase 3ibrutinib (Janssen Biotech/Pharmacyclics)diffuse large B-cell lymphoma, myeloma/chronic lymphocytic leukemia,mantle cell lymphomaphase 2/phase 3ICT-107 (ImmunoCellular Therapeutics)glioblastomaphase 2i
Oncology Drugs in the Pipeline HemOnc Today presents the most recent information about oncology drugs in the pipeline. Drugs listed here are in phase 2 or phase 3 development for a variety of indications. Clinicians can use this chart as a quick reference to learn about the status of tho
May 02, 2018 · D. Program Evaluation ͟The organization has provided a description of the framework for how each program will be evaluated. The framework should include all the elements below: ͟The evaluation methods are cost-effective for the organization ͟Quantitative and qualitative data is being collected (at Basics tier, data collection must have begun)
Silat is a combative art of self-defense and survival rooted from Matay archipelago. It was traced at thé early of Langkasuka Kingdom (2nd century CE) till thé reign of Melaka (Malaysia) Sultanate era (13th century). Silat has now evolved to become part of social culture and tradition with thé appearance of a fine physical and spiritual .
On an exceptional basis, Member States may request UNESCO to provide thé candidates with access to thé platform so they can complète thé form by themselves. Thèse requests must be addressed to esd rize unesco. or by 15 A ril 2021 UNESCO will provide thé nomineewith accessto thé platform via their émail address.
̶The leading indicator of employee engagement is based on the quality of the relationship between employee and supervisor Empower your managers! ̶Help them understand the impact on the organization ̶Share important changes, plan options, tasks, and deadlines ̶Provide key messages and talking points ̶Prepare them to answer employee questions
Dr. Sunita Bharatwal** Dr. Pawan Garga*** Abstract Customer satisfaction is derived from thè functionalities and values, a product or Service can provide. The current study aims to segregate thè dimensions of ordine Service quality and gather insights on its impact on web shopping. The trends of purchases have
Oncology Drugs in the Pipeline HemOnc Today’s annual Oncology Drugs in the Pipeline chart lists agents in phase 2 or phase 3 development
Chính Văn.- Còn đức Thế tôn thì tuệ giác cực kỳ trong sạch 8: hiện hành bất nhị 9, đạt đến vô tướng 10, đứng vào chỗ đứng của các đức Thế tôn 11, thể hiện tính bình đẳng của các Ngài, đến chỗ không còn chướng ngại 12, giáo pháp không thể khuynh đảo, tâm thức không bị cản trở, cái được
ALBERT WOODFOX CIVIL ACTION VERSUS NO. 06-789-JJB BURL CAIN, WARDEN, LOUISIANA STATE PENITENTIARY, ET AL RULING This matter is before the Court on Petitioner Albert Woodfox’s (“Woodfox”) petition for habeas relief on the claim that Woodfox’s March 1993 indictment by a West Feliciana Parish grand jury was tainted by grand jury foreperson discrimination. An evidentiary hearing was held .
